A
Alcista
Alcista · 25%SPRC
$7.05
Precio del escenario
$1.700
-0.255 (-15.00%)Al cierre
Loading chart…
- Máximo
- 1.970
- Apertura
- 1.770
- Precio medio ponderado por volumen
- 1.76
- Volumen
- 391.19K
- Capitalización
- 2.77M
- Mínimo
- 1.600
- Importe
- 687.20K
- EV/EBITDA, TTM
- 0.00
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Análisis de IA of Scisparc Ltd (SPRC)
VenderGiven the current price of $1.70 and an RSI of 6.99, which indicates extreme oversold conditions, there may be potential for a short-term bounce. However, the stock has experienced a staggering 95.62% decline over the past year and a 61.97% drop in the last five days, indicating severe underlying issues. The forward P/E ratio is 0, suggesting no earnings growth is expected in the near future, and the gross margin has dropped to 0% in the latest quarter, reflecting significant operational challenges. The main risk is the company's negative EPS of -299.94 for Q4 2025, indicating ongoing losses. Therefore, while there may be a potential for recovery, the current financial health and performance metrics suggest that this is not a good time to buy.
Métricas de valoración
El PER previsto actual de Scisparc Ltd (SPRC) es 0.00, frente a su media de 5 años de -7.85.
Escenarios de precio de Alphio AI para SPRC
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
4.510-15NewsfilterSciSparc Shifts Strategic Focus to Agentic AI Technologies
- 8.509-02Newsfilter
NeuroThera Pursues FDA Orphan Drug Designation for SCI-110
- 4.508-26Newsfilter
SciSparc Appoints AI Expert to Strengthen Strategic Focus
- 8.508-12Newsfilter
NeuroThera Secures Japanese Patent for Pain Treatment
9.008-05GlobenewswireSciSparc Initiates NeuroThera Phase IIb Clinical Trial
Preguntas frecuentes sobre SPRC, respondidas por Alphio AI
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Given the current price of $1.70 and an RSI of 6.99, which indicates extreme oversold conditions, there may be potential for a short-term bounce. However, the stock has experienced a staggering 95.62% decline over the past year and a 61.97% drop in the last five days, indicating severe underlying issues. The forward P/E ratio is 0, suggesting no earnings growth is expected in the near future, and the gross margin has dropped to 0% in the latest quarter, reflecting significant operational challenges. The main risk is the company's negative EPS of -299.94 for Q4 2025, indicating ongoing losses. Therefore, while there may be a potential for recovery, the current financial health and performance metrics suggest that this is not a good time to buy.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.